Works matching IS 1007385X AND DT 2022 AND VI 29 AND IP 6
1
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 596, doi. 10.3872/j.issn.1007-385x.2022.06.012
- Article
2
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 587, doi. 10.3872/j.issn.1007-385x.2022.06.011
- Article
3
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 580, doi. 10.3872/j.issn.1007-385x.2022.06.010
- Article
4
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 571, doi. 10.3872/j.issn.1007-385x.2022.06.009
- Article
5
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 567, doi. 10.3872/j.issn.1007-385x.2022.06.008
- Article
6
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 557, doi. 10.3872/j.issn.1007-385x.2022.06.007
- Article
7
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 549, doi. 10.3872/j.issn.1007-385x.2022.06.006
- Article
8
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 541, doi. 10.3872/j.issn.1007-385x.2022.06.005
- Article
9
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 534, doi. 10.3872/j.issn.1007-385x.2022.06.004
- Article
10
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 527, doi. 10.3872/j.issn.1007-385x.2022.06.003
- Article
11
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 519, doi. 10.3872/j.issn.1007-385x.2022.06.002
- Article
12
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 6, p. 509, doi. 10.3872/j.issn.1007-385x.2022.06.001
- Article